Clinical Trials & Research
Oftentimes, when people think about medical research and clinical trials, they believe that the most advanced trials are only accessible at hospital organizations. This is not true! Child Neurology & Consultants of Austin is at the forefront of pediatric neurosciences research — making available new medicines and technologies to patients via clinical trials.
All clinical trial participation is optional for patients and is not required for clinical care. If you have questions about joining a study, please speak to your child’s physician or contact our clinical coordinator. Additional studies may be available soon.
Ongoing Studies
Description |
Focus |
|
|---|---|---|
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children with Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab (SKYRIZI®) or Adalimumab (HUMIRA®) – “KnaPsAck Study” Primary Investigator: Ruy Carrasco, MD Status: Ongoing, OPEN to Enrollment Primary Investigator: Ruy Carrasco, MD Status: Ongoing, OPEN to Enrollment |
Juvenile Psoriatic Arthritis (jPsA) | |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup Study to Evaluate the Efficacy and Safety of Erenumab (Aimovig®) in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine – “OASIS(EM) Study” Primary Investigator: Riddhiben Patel, MD Status: Ongoing, OPEN to Enrollment |
Preventative Treatment of Episodic Migraine | |
| A Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant (Nurtec®) for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age Primary Investigator: Katherine Labiner, MD Status: Ongoing, OPEN to Enrollment |
Acute Treatment of Migraine | More information |
| A Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant (Nurtec®) for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age Primary Investigator: Katherine Labiner, MD Status: Ongoing, OPEN to Enrollment |
Acute Treatment of Migraine | |
| A 20-Week Multicenter, Randomized, Double-Blind, PlaceboControlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Patients with Dravet Syndrome (DS) – “ARGUS Study" Primary Investigator: Karen Keough, MD Status: Ongoing, OPEN to Enrollment |
Epilepsy – DS | More information |
| An Expanded Access Program (EAP) for Treatment with LP352 (Bexicaserin) for Patients with Developmental and Epileptic Encephalopathies (DEEs) – “PACIFIC EAP Study” Primary Investigator: Karen Keough, MD Status: Ongoing, OPEN to Enrollment |
Epilepsy – DEEs | More information |
| An Open-Label Safety and Efficacy Study of Cenobamate (XCOPRI® ) in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures Primary Investigator: Karen Keough, MD Status: Ongoing, OPEN to Enrollment |
Focal Epilepsy | More information |
| An Observational Registry of Abatacept (ORENCIA®) in Patients with Juvenile Idiopathic Arthritis (JIA) Primary Investigator: Ruy Carrasco, MD Status: Ongoing, CLOSED to Enrollment |
Juvenile Idiopathic Arthritis (JIA) | More information |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, FixedDose, Multicenter Study to Examine the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride [FINTEPLA® ]) In Subjects with Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (CDD) Followed by an Open-Label Extension – “GEMZ Study” Primary Investigator: Karen Keough, MD Status: Ongoing, CLOSED to Enrollment |
Epilepsy – CDD | More information |
Closed Studies
Description |
Focus |
|
|---|---|---|
| A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy – “TrustTSC OLE Study” Primary Investigator: Karen Keough, MD |
TSC-Related Epilepsy | |
| A Phase 3, Doubleblind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-Related Epilepsy – “TrustTSC Study” Primary Investigator: Karen Keough, MD |
TSC-Related Epilepsy | |
| An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel (FYCOMPA®) Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to less than 18 Years) with Childhood Epilepsy Primary Investigator: Karen Keough, MD |
Pediatric Epilepsy | More information |
| An Open-Label, LongTerm Safety Study of LP352 (Bexicaserin) in Subjects with Developmental and Epileptic Encephalopathy (DEE) – “PACIFIC OLE Study” Primary Investigator:Karen Keough, MD |
Epilepsy - DEEs | |
| A Randomized, DoubleBlind, PlaceboControlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate (XCOPRI® ) Adjunctive Therapy in Subjects with PGTC Seizures Primary Investigator: Karen Keough, MD |
Primary Generalized Epilepsy | More information |
| A Randomized, DoubleBlind, PlaceboControlled, ParallelGroup, Dose-Escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 (Bexicaserin) in Subjects with Developmental and Epileptic Encephalopathies (DEEs) – “PACIFIC Study” Primary Investigator: Karen Keough, MD |
Epilepsy – DEEs | More information |
| CORE-VNS: Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy Primary Investigator: Karen Keough, MD |
Pediatric Epilepsy | More information |
| An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007 [FYCOMPA®]) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 Years of Age with Epilepsy Primary Investigator: Katherine Labiner, MD |
Pediatric Epilepsy | More information |
To find out more about our clinical trials, email Child Neurology & Consultants of Austin’s two research coordinators, Victoria Henderson & Talitha Durgin, at victoria.henderson@childneurotx.com & talitha.durgin@childneurotx.com.
